Marker Therapeutics, Inc. — Director's Dealing 2017

Aug 30, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC. (TPIV)
CIK: 0001094038
Period of Report: 2017-08-29

Reporting Person: Wasserman Frederick Gerald (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-29	Common Stock	A	13115	—	Acquired	13115	Direct

Footnotes

F1: Represents the portion of the annual retainer for each non-employee director payable in immediately vested restricted, common stock under the Company's 2014 Omnibus Stock Ownership Plan and based on the closing price of $3.05 per share, on the day immediately preceding the date of the Company's 2017 annual meeting.